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codes as independent variables and the logit of progression degree as a dependent 
variable. Results: 1,436 target patients were extracted from the database. When 
the actual progression degree is over 80%, the estimated progression degree rises 
with the actual degree, however, at the lower progression degrees, the estimated 
degree was excessively overestimated. ConClusions: We have developed a model 
to estimate the progression degree in colon cancer. The model estimates the pro-
gression degree well only for the last phase patients. The model should further be 
improved to minimize the bias at the lower degree.
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objeCtives: Overall survival (OS) remains the gold standard measure of clini-
cal efficacy for oncology clinical trials due to its objective nature and consistency 
between diseases and treatments. However, given recent advances in treatments, 
and prolonged survival, OS benefits are becoming more challenging to establish, 
requiring more extensive follow-up. A number of methods to test this rationale 
have been developed but these often lack adequate data, relying solely on mean or 
median survival. Recognising these limitations, we developed an alternative meth-
odology whereby surrogacy is established over time, to ensure that a surrogate is 
not only valid at the mean, but also throughout treatment duration. Methods: A 
number of different survival points were derived from selected oncology trials by 
digitizing available survival curves. PlotDigitizer 2.6.4 software was used to establish 
time points for 10%, 25%, 50%, 75%, and 90% OS and progression-free survival (PFS). 
Correlation and regression analysis were evaluated at these percentiles based on 
survival times. Patient populations between the clinical trials were comparable to 
one another. Statistical analysis was conducted in STATA 12. Results: Correlation 
analysis found the strongest association between PFS and OS between 75% and 
25% survival (0.865 to 0.953; p< 0.01), with a weak association at 90% survival (0.61; 
p= 0.096). Regression analysis also found that PFS had the largest influence on OS 
between 75% and 25% survival (R2> 0.75). ConClusions: Given the varying nature 
of how patients progress across and within types of therapies, it is essential to 
ensure the surrogacy of the endpoint across the full trial duration. For example, 
patients may progress early on in a disease and surrogacy may not be consistent 
across different time points. Additionally, in evaluating older studies, using this 
approach of scanning survival data will provide a richer picture of the disease area 
that may no longer be available from authors or research institutions.
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bACkgRound: Overactive bladder(OAB) is characterized by symptoms of urgency, 
incontinence, frequency and nocturia. With the syndromic nature of the condition, 
clinical trials often solely report the most effective outcome i.e. the symptom with 
the largest improvement. As a result different interventions are evaluated for dif-
ferent outcomes, which can have severe implications for network meta-analyses, 
and consequently, decision-making. objeCtives: To evaluate the use of multivari-
ate network meta-analysis(MVNMA) to identify the most effective intervention for 
treating OAB syndrome. Methods: Using Bayesian Markov Chain Monte Carlo 
methods, we developed MVNMA accounting for the correlation between multiple 
outcomes to predict treatment effects for missing data. We extended this model to 
incorporate the exchangeability between treatment effects of the same interven-
tion with different methods of administration (e.g. immediate release, extended 
release, intravesical etc.) and incorporated dose-response constraints on increasing 
doses. The outcomes of interest were mean change from baseline in incontinence, 
and urgency episodes. Results: Independently, the datasets included 109 and 56 
trials, evaluating 93 and 51 interventions, for incontinence and urgency episodes 
respectively. Sacral nerve stimulation appeared to be the most effective intervention 
for reducing incontinence with an estimated mean reduction of -8.9(95%CrI:-10.9,-
7) episodes per 24hours relative to placebo. For urgency, sacral nerve stimulation 
was disconnected from the network and thus could not be not evaluated. Borrowing 
information between outcomes, the dataset for multivariate analyses included 117 
trials evaluating all 95 treatments for OAB. Sacral nerve stimulation appeared to be 
the most effective intervention for both incontinence and urgency episodes with an 
estimated mean reduction of -8.3(95%CrI:-10.1,-6.9) and -9.1(95%CrI:-10.5,-7.3) epi-
sodes, respectively. ConClusions: Sacral nerve stimulation appeared to be the most 
effective intervention for treating OAB symptoms. MVNMA allowed us to evaluate 
all interventions across all outcomes, and in this case also increased precision in 
treatment effect estimates. Further work includes adjustment for baseline severity.
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objeCtives: The clinical endpoints selected for oncology trials have to meet the 
needs of diverse stakeholders: patients, clinicians, regulators, and HTA agencies, each 
with a different perspective. PFS is becoming a more widely accepted measure of 
treatment efficacy, but there is tension between regulators and payors regarding its 
acceptability. This study investigated PFS as a valid and credible endpoint from the 
perspectives of relevant decision-makers. Methods: Published and gray literature 
(2005–2015) were searched for regulatory and HTA guidance on PFS as an endpoint. 
We identified examples of decisions by regulators and HTA agencies in which PFS 
tended to be protective of discontinuations due to adverse events relative to stand-
ard dose EFV. Use of arm-specific regression supplemented by endonodal trials led 
to tighter confidence intervals facilitating decision-making. Specifically, DTG was 
consequently superior to EFV with respect to CD4 cell counts and raltegravir was 
distinguishable from EFV when it was not otherwise. ConClusions: Making full 
use of available evidence is the focal strength of NMA methodology. Therefore, we 
recommend use of endonodal trials to further supplement evidence bases requiring 
arm-specific meta-regression.
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objeCtives: In an absence of randomized controlled trials (RCTs) and to verify RCT 
evidence, health technology assessment (HTA) agencies commonly rely on real-
world (RW) studies to provide efficacy evidence for healthcare interventions. RW 
study designs can introduce considerable bias into a systematic review (SR) and sev-
eral methodologies exist to evaluate the risk of bias in such studies. We conducted a 
series of reviews to identify which tools are commonly used and which are recom-
mended by HTA bodies. Methods: A targeted search of SRs including RW studies, 
conducted in MEDLINE and EMBASE (OVID SP), identified reviews published January 
2013-June 2015. Studies identified were reviewed to determine which appraisal tool 
was used. Secondly, recommendations for the critical appraisal of RW studies by 
expert review groups (Cochrane, CRD) and HTA bodies (NICE, SMC, NCPE, AWMSG, 
IQWiG, PBAC, AMCP, AHRQ and CADTH) were reviewed. Results: 1885 studies were 
identified and screened. Commonly used tools included Downs & Black, Chalmers, 
the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither Cochrane nor CRD 
recommend a particular risk of bias instrument. The AHRQ developed the MORE 
checklist following a SR of existing critical appraisal tools. Of the other HTA bodies 
only CADTH recommend use of a specific critical appraisal tool; SIGN 50 (for cohort 
or case-control studies). The tools identified examine a variety of criteria including 
reporting, external validity, bias, confounding, and power. ConClusions: There 
is no consensus on a preferred instrument that allows for the assessment of all 
types of RW evidence and critical appraisal of RW evidence is often omitted from 
HTA submissions. There is thus a need for cross communication between groups 
to reach a consensus and develop a suitable tool. Until a suitable tool is developed, 
reviewers should select the most appropriate checklist for the design of the studies 
identified in a particular SR.
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objeCtives: Sample quality in prospective long-term drug safety studies can 
be impaired by selective lost-to-follow-up. Attrition will especially bias the sam-
ple, when patients with relevant risk factors selectively drop out. In this case, 
effects in endpoints cannot be related to study-relevant independent variables. 
The present contribution will demonstrate how careful follow-up procedures can 
prevent disease-related drop-out bias of the sample. Methods: For a long-term 
prospective safety study of new Oral Contraceptive (OC) 25,213 women aged 20 
to 40 years were enrolled from gynecological practices in Germany. The women 
filled-in a baseline questionnaire and were followed-up over two years with four 
follow-up questionnaires in total. Whenever safety-relevant signs were reported in 
the questionnaires, physicians validated the report. After two years 12,823 women 
were still in the sample and completed the fourth questionnaire. Disease differ-
ences between the “Retained” and the “Lost” group, which could indicate sample 
bias, were analysed using multivariate methods. Results: The “retained” and the 
“lost-to-follow-up” group did not differ in initial disease status or in risk factor at 
study start: High blood pressure: 2.9% in “Retained Group”; 2.7% in “Lost Group” 
(phi= .006; n.s.), diabetes : 0.6% vs. 0.6% (phi= .001; n.s.), high cholesterol: 2.6% vs. 
2.4% (phi= .007; n.s.),venous thrombosis : .8% vs. .8% (phi= .002; n.s.), smoker-rate : 
34.9% vs. 42.3% (phi= .127), BMI> 30: r= .004 (n.s.), age r= .048 (n.s.). The results show 
that drop-out of the initial sample is not related to study relevant morbidity and 
that sample bias cannot be concluded. ConClusions: Careful follow-up methods 
guarantee low lost-to-follow-up in longterm prospective studies of drug safety. 
Since drop-out cannot be attributed to study-relevant confounders, attrition does 
not lead to sample bias.
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objeCtives: Accurate determination of the progression degree in colon cancer is 
of paramount importance for the decision making in treatment policy. However, 
it had been difficult to extract the exacerbation status from the real-world data. 
The objective of the study was to develop the model to determinate the progres-
sion degree using the insurance benefits data in Japan. Methods: We conducted 
analyses using claims data provided by Medical Data Vision Co., Ltd. We extracted 
target patients by the criteria those who meets all of the following conditions; 
at least one colon cancer diagnosis (ICD-10 code C18~20), tractable from the first 
diagnosis to death, and have at least 365 days of observation. We set the progression 
degree as a scale from 0% to 100%. The degree of 100% indicates the patient death. 
For the first diagnosis, the scale was adjusted based on the patient’s condition. We 
have developed a linear regression model by using the medication frequency of ATC 
